Arabic Arabic English English French French German German
dark

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.6 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Benefits of Flexible Packaging for Medical Devices Now Include Child Resistance

Next Post

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting

Related Posts
Total
0
Share